Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
Summary
By targeting GIP directly, weve rapidly advanced a differentiated portfolio that may deliver superior treatment outcomes through enhanced efficacy, tolerability, and convenient dosing regimens." Helicores approach leverages insights from human genetics, proprietary preclinical data, and third-party clinical studies to design compelling target product profiles. Individuals carrying genetic loss-of-function mutations in either GIP or GIPR are protected from obesity and exhibit lean phenotypes thought to arise from diminished GIP/GIPR-mediated triglyceride uptake in adipocytes (fat cells). "Helicores novel approach is backed by robust evidence and could offer cardiometabolic benefits alongside quality weight loss and improved tolerability when combined with GLP-1. The company is poised to make rapid progress in 2025 advancing HCR-188 as well as an exciting portfolio of antibody conjugates already under development that have long-term value-creating potential.